230 related articles for article (PubMed ID: 27568559)
1. Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers.
Goldstein LD; Lee J; Gnad F; Klijn C; Schaub A; Reeder J; Daemen A; Bakalarski CE; Holcomb T; Shames DS; Hartmaier RJ; Chmielecki J; Seshagiri S; Gentleman R; Stokoe D
Cell Rep; 2016 Sep; 16(10):2605-2617. PubMed ID: 27568559
[TBL] [Abstract][Full Text] [Related]
2. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
Namani A; Matiur Rahaman M; Chen M; Tang X
BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
[TBL] [Abstract][Full Text] [Related]
3. A Naturally-Occurring Dominant-Negative Inhibitor of Keap1 Competitively against Its Negative Regulation of Nrf2.
Qiu L; Wang M; Zhu Y; Xiang Y; Zhang Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30042301
[TBL] [Abstract][Full Text] [Related]
4.
Akdemir B; Nakajima Y; Inazawa J; Inoue J
Mol Cancer Res; 2017 Nov; 15(11):1570-1578. PubMed ID: 28760781
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic mutations in KEAP1 disturbing inhibitory Nrf2-Keap1 interaction: Activation of antioxidative pathway in papillary thyroid carcinoma.
Danilovic DLS; de Mello ES; Frazzato EST; Wakamatsu A; de Lima Jorge AA; Hoff AO; Marui S
Head Neck; 2018 Jun; 40(6):1271-1278. PubMed ID: 29469959
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
[TBL] [Abstract][Full Text] [Related]
7. KEAP1/NRF2 signaling pathway mutations in cervical cancer.
Chu XY; Li ZJ; Zheng ZW; Tao YL; Zou FX; Yang XF
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4458-4466. PubMed ID: 30058679
[TBL] [Abstract][Full Text] [Related]
8. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma.
Fabrizio FP; Costantini M; Copetti M; la Torre A; Sparaneo A; Fontana A; Poeta L; Gallucci M; Sentinelli S; Graziano P; Parente P; Pompeo V; De Salvo L; Simone G; Papalia R; Picardo F; Balsamo T; Flammia GP; Trombetta D; Pantalone A; Kok K; Paranita F; Muscarella LA; Fazio VM
Oncotarget; 2017 Feb; 8(7):11187-11198. PubMed ID: 28061437
[TBL] [Abstract][Full Text] [Related]
9. Effects of KEAP1 Silencing on the Regulation of NRF2 Activity in Neuroendocrine Lung Tumors.
Sparaneo A; Fabrizio FP; la Torre A; Graziano P; Di Maio M; Fontana A; Bisceglia M; Rossi A; Pizzolitto S; De Maglio G; Tancredi A; Grimaldi F; Balsamo T; Centra F; Manzorra MC; Trombetta D; Pantalone A; Bonfitto A; Maiello E; Fazio VM; Muscarella LA
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126053
[TBL] [Abstract][Full Text] [Related]
10. Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405.
Probst BL; McCauley L; Trevino I; Wigley WC; Ferguson DA
PLoS One; 2015; 10(8):e0135257. PubMed ID: 26301506
[TBL] [Abstract][Full Text] [Related]
11. WDR23 regulates NRF2 independently of KEAP1.
Lo JY; Spatola BN; Curran SP
PLoS Genet; 2017 Apr; 13(4):e1006762. PubMed ID: 28453520
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
13. Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway.
Shibata T; Saito S; Kokubu A; Suzuki T; Yamamoto M; Hirohashi S
Cancer Res; 2010 Nov; 70(22):9095-105. PubMed ID: 21062981
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
[TBL] [Abstract][Full Text] [Related]
15. NRF2 DLG Domain Mutations Identified in Japanese Liver Cancer Patients Affect the Transcriptional Activity in HCC Cell Lines.
Haque E; Śmiech M; Łuczyńska K; Bouchard MF; Viger R; Kono H; Pierzchała M; Taniguchi H
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069882
[TBL] [Abstract][Full Text] [Related]
16. NRF2-Dependent Bioactivation of Mitomycin C as a Novel Strategy To Target KEAP1-NRF2 Pathway Activation in Human Cancer.
Baird L; Yamamoto M
Mol Cell Biol; 2021 Jan; 41(2):. PubMed ID: 33139492
[TBL] [Abstract][Full Text] [Related]
17. The NRF2 transcriptional target NQO1 has low mRNA levels in TP53-mutated endometrial carcinomas.
Beinse G; Just PA; Rance B; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Pasmant E; Batteux F; Borghese B; Alexandre J; Leroy K
PLoS One; 2019; 14(3):e0214416. PubMed ID: 30908539
[TBL] [Abstract][Full Text] [Related]
18. A catalogue of somatic NRF2 gain-of-function mutations in cancer.
Kerins MJ; Ooi A
Sci Rep; 2018 Aug; 8(1):12846. PubMed ID: 30150714
[TBL] [Abstract][Full Text] [Related]
19. NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma.
Cescon DW; She D; Sakashita S; Zhu CQ; Pintilie M; Shepherd FA; Tsao MS
Clin Cancer Res; 2015 Jun; 21(11):2499-505. PubMed ID: 25739673
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-200a controls Nrf2 activation by target Keap1 in hepatic stellate cell proliferation and fibrosis.
Yang JJ; Tao H; Hu W; Liu LP; Shi KH; Deng ZY; Li J
Cell Signal; 2014 Nov; 26(11):2381-9. PubMed ID: 25049078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
